ProCE Banner Activity

CE / CME

Practical Guidance on Optimizing Management of Follicular Lymphoma

Text Module

Get up to date on optimal management of follicular lymphoma with multidisciplinary expert perspectives on selecting frontline therapy, sequencing treatments for relapsed or refractory disease, and utilizing rituximab biosimilars and alternative formulations, along with promising investigational agents.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Nurses: 1.25 Nursing contact hours

Released: November 20, 2020

Expiration: November 19, 2021

No longer available for credit.

Share

Faculty

Emily Bucholtz

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Nichole Fisher

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Celgene

Epizyme, Inc.

Target Audience

This program is intended for physicians, pharmacists, nurses, and other healthcare providers who care for patients with follicular lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal therapy for patients with FL in the frontline and relapsed/refractory settings based on current risk stratification methods and prognostic indices
  • Evaluate emerging treatment options for the management of patients with newly diagnosed FL 
  • Describe novel therapeutic options for patients with FL after 2 or more lines of therapy
  • Consider the potential differences in the mechanisms of action and efficacy and safety profile of different agents within the same drug class to select treatments most likely to improve clinical outcomes in patients with FL
  • Outline strategies to integrate novel therapies into current FL clinical practice
  • Identify patients with FL who are candidates for ongoing clinical trials

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Emily Bucholtz, RPh, has no relevant conflicts of interest to report.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics, and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutics.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG Therapeutics, and consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutics.

Nichole Fisher, RN, BSN

Supervisor, Clinical Research
Willamette Valley Cancer Institute & Research Center
Eugene, Oregon 

Nichole Fisher, RN, BSN, has disclosed that she has received consulting fees from AbbVie and MorphoSys, has received other financial or material support from AstraZeneca, and has ownership interest in TG Therapeutics.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-134-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 20, 2020, through November 19, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment for patients with follicular lymphoma.